208 related articles for article (PubMed ID: 12445254)
1. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C
Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254
[TBL] [Abstract][Full Text] [Related]
2. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
3. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.
Pautier P; Rey A; Haie-Meder C; Kerbrat P; Dutel JL; Gesta P; Bryard F; Morice P; Duvillard P; Lhommé C
Int J Gynecol Cancer; 2004; 14(6):1112-7. PubMed ID: 15571617
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.
Odunsi K; Moneke V; Tammela J; Ghamande S; Seago P; Driscoll D; Marchetti D; Baker T; Lele S
Int J Gynecol Cancer; 2004; 14(4):659-64. PubMed ID: 15304162
[TBL] [Abstract][Full Text] [Related]
6. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
Edmonson JH; Marks RS; Buckner JC; Mahoney MR
Cancer Invest; 2002; 20(5-6):605-12. PubMed ID: 12197215
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors.
Peters WA; Rivkin SE; Smith MR; Tesh DE
Gynecol Oncol; 1989 Sep; 34(3):323-7. PubMed ID: 2767523
[TBL] [Abstract][Full Text] [Related]
8. Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary.
Baker TR; Piver MS; Caglar H; Piedmonte M
Am J Clin Oncol; 1991 Jun; 14(3):246-50. PubMed ID: 2031513
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
[TBL] [Abstract][Full Text] [Related]
10. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Pautier P; Floquet A; Gladieff L; Bompas E; Ray-Coquard I; Piperno-Neumann S; Selle F; Guillemet C; Weber B; Largillier R; Bertucci F; Opinel P; Duffaud F; Reynaud-Bougnoux A; Delcambre C; Isambert N; Kerbrat P; Netter-Pinon G; Pinto N; Duvillard P; Haie-Meder C; Lhommé C; Rey A
Ann Oncol; 2013 Apr; 24(4):1099-104. PubMed ID: 23139262
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes with intraoperative radiotherapy as a component of treatment for locally advanced or recurrent uterine sarcoma.
Barney BM; Petersen IA; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):191-7. PubMed ID: 21985942
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Piura B; Rabinovich A
Eur J Gynaecol Oncol; 2005; 26(3):275-8. PubMed ID: 15991525
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer.
Lupera H; Theodore C; Ghosn M; Court BH; Wibault P; Droz JP
Urology; 1989 Nov; 34(5):281-3. PubMed ID: 2815451
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Hirota Y; Miyamura K; Hayata T; Miyakawa I
Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960
[TBL] [Abstract][Full Text] [Related]
18. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.
Hensley ML
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):773-82. PubMed ID: 21752717
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
20. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]